Investigation for Investors in shares of Galapagos NV (NASDAQ: GLPG) announced

An investigation was announced concerning potential securities laws violations by Galapagos NV in connection with certain financial statements.

Investors who purchased shares of Galapagos NV (NASDAQ: GLPG), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Galapagos NV regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Belgium based Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Galapagos NV reported that its annual Total Revenue rose from 288.83 million EUR in 2018 to 844.98 million EUR in 2019, and that Net Loss of 28.42 million EUR in 2018 turned to a Net Income of 416.38 million EUR.

On August 18, 2020, Galapagos NV disclosed that its collaborative partner, Gilead Sciences, Inc. ("Gilead"), had received a Complete Response Letter from the U.S. Food and Drug Administration ("FDA") for the New Drug Application ("NDA") for filgotinib, an investigational treatment for moderately to severely active rheumatoid arthritis. Galapagos advised investors that "[t]he FDA has requested data from the MANTA and MANTA-RAy studies before completing its review of the NDA. The MANTA and MANTA-RAy studies are designed to assess whether filgotinib has an impact on sperm parameters. The FDA also has expressed concerns regarding the overall benefit/risk profile of the filgotinib 200 mg dose."

Shares of Galapagos NV (NASDAQ: GLPG) declined from $209.95 per share in July 2020 to as low as $113.03 per share in November 2020.

Those who purchased shares of Galapagos NV (NASDAQ: GLPG) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.